BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 28912154)

  • 41. Changes in the prefrontal cortex after the hippocampus was injected with Aβ
    Wang Y; Sheng H; Zhao J; Guo L; Liu J; Xu J; Liu Q; Huang J; Jiang R; Gan S; Qiu G; Lu W; Xu S; Zhu S
    Neurosci Lett; 2021 Jan; 741():135453. PubMed ID: 33186609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy.
    Giannopoulos PF; Chu J; Sperow M; Li JG; Yu WH; Kirby LG; Abood M; Praticò D
    Biol Psychiatry; 2015 Nov; 78(10):693-701. PubMed ID: 25802082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs.
    Nakamura M; Shiozawa S; Tsuboi D; Amano M; Watanabe H; Maeda S; Kimura T; Yoshimatsu S; Kisa F; Karch CM; Miyasaka T; Takashima A; Sahara N; Hisanaga SI; Ikeuchi T; Kaibuchi K; Okano H
    Stem Cell Reports; 2019 Oct; 13(4):684-699. PubMed ID: 31543469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes.
    Pao PC; Seo J; Lee A; Kritskiy O; Patnaik D; Penney J; Raju RM; Geigenmuller U; Silva MC; Lucente DE; Gusella JF; Dickerson BC; Loon A; Yu MX; Bula M; Yu M; Haggarty SJ; Tsai LH
    Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2217864120. PubMed ID: 37043533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative and combinatory determination of in situ phosphorylation of tau and its FTDP-17 mutants.
    Kimura T; Hosokawa T; Taoka M; Tsutsumi K; Ando K; Ishiguro K; Hosokawa M; Hasegawa M; Hisanaga S
    Sci Rep; 2016 Sep; 6():33479. PubMed ID: 27641626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cdk5 is a key factor in tau aggregation and tangle formation in vivo.
    Noble W; Olm V; Takata K; Casey E; Mary O; Meyerson J; Gaynor K; LaFrancois J; Wang L; Kondo T; Davies P; Burns M; Veeranna ; Nixon R; Dickson D; Matsuoka Y; Ahlijanian M; Lau LF; Duff K
    Neuron; 2003 May; 38(4):555-65. PubMed ID: 12765608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.
    Binukumar BK; Pelech SL; Sutter C; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
    J Alzheimers Dis; 2016 Sep; 54(2):525-33. PubMed ID: 27567857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
    Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
    J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
    McKenzie-Nickson S; Chan J; Perez K; Hung LW; Cheng L; Sedjahtera A; Gunawan L; Adlard PA; Hayne DJ; McInnes LE; Donnelly PS; Finkelstein DI; Hill AF; Barnham KJ
    ACS Chem Neurosci; 2018 Nov; 9(11):2731-2740. PubMed ID: 29920069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity.
    Chen J; Li S; Sun W; Li J
    PLoS One; 2015; 10(4):e0123864. PubMed ID: 25875370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ameliorating Alzheimer's-like Pathology by Minocycline via Inhibiting Cdk5/p25 Signaling.
    Zhao Y; Wang C; He W; Cai Z
    Curr Neuropharmacol; 2022 Aug; 20(9):1783-1792. PubMed ID: 34856907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.
    Chalermpalanupap T; Schroeder JP; Rorabaugh JM; Liles LC; Lah JJ; Levey AI; Weinshenker D
    J Neurosci; 2018 Jan; 38(1):74-92. PubMed ID: 29133432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy.
    Vagnozzi AN; Giannopoulos PF; Praticò D
    Transl Psychiatry; 2017 Dec; 7(12):1288. PubMed ID: 29249809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypoxia increases Aβ-induced tau phosphorylation by calpain and promotes behavioral consequences in AD transgenic mice.
    Gao L; Tian S; Gao H; Xu Y
    J Mol Neurosci; 2013 Sep; 51(1):138-47. PubMed ID: 23345083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amyloid-β Fosters p35/CDK5 Signaling Contributing to Changes of Inhibitory Synapses in Early Stages of Cerebral Amyloidosis.
    Kiss E; Groeneweg F; Gorgas K; Schlicksupp A; Kins S; Kirsch J; Kuhse J
    J Alzheimers Dis; 2020; 74(4):1167-1187. PubMed ID: 32144981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
    Ramsden M; Kotilinek L; Forster C; Paulson J; McGowan E; SantaCruz K; Guimaraes A; Yue M; Lewis J; Carlson G; Hutton M; Ashe KH
    J Neurosci; 2005 Nov; 25(46):10637-47. PubMed ID: 16291936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glutamate treatment and p25 transfection increase Cdk5 mediated tau phosphorylation in SH-SY5Y cells.
    Jämsä A; Bäckström A; Gustafsson E; Dehvari N; Hiller G; Cowburn RF; Vasänge M
    Biochem Biophys Res Commun; 2006 Jun; 345(1):324-31. PubMed ID: 16678793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
    Hisanaga S; Saito T
    Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.
    Van den Haute C; Spittaels K; Van Dorpe J; Lasrado R; Vandezande K; Laenen I; Geerts H; Van Leuven F
    Neurobiol Dis; 2001 Feb; 8(1):32-44. PubMed ID: 11162238
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.